Abstract
Gestational diabetes mellitus (GDM) associates with increased L-arginine transport and extracellular concentration of adenosine in human umbilical vein endothelial cells (HUVECs). In this study we aim to determine whether insulin reverses GDM-increased L-arginine transport requiring adenosine receptors expression in HUVECs. Primary cultured HUVECs from full-term normal (n = 38) and diet-treated GDM (n = 38) pregnancies were used. Insulin effect was assayed on human cationic amino acid transporter 1 (hCAT1) expression (protein, mRNA, SLC7A1 promoter activity) and activity (initial rates of L-arginine transport) in the absence or presence of adenosine receptors agonists or antagonists. A1 adenosine receptors (A1AR) and A2AAR expression (Western blot, quantitative PCR) was determined. Experiments were done in cells expressing or siRNA-suppressed expression of A1AR or A2AAR. HUVECs from GDM exhibit higher maximal transport capacity (maximal velocity (V max)/apparent Michaelis Menten constant (K m), V max/K m), which is blocked by insulin by reducing the V max to values in cells from normal pregnancies. Insulin also reversed the GDM-associated increase in hCAT-1 protein abundance and mRNA expression, and SLC7A1 promoter activity for the fragment −606 bp from the transcription start point. Insulin effects required A1AR, but not A2AAR expression and activity in this cell type. In the absence of insulin, GDM-increased hCAT-1 expression and activity required A2AAR expression and activity. HUVECs from GDM pregnancies exhibit a differential requirement of A1AR or A2AAR depending on the level of insulin, a phenomenon that represent a condition where adenosine or analogues of this nucleoside could be acting as helpers of insulin biological effects in GDM.
Similar content being viewed by others
Abbreviations
- GDM:
-
Gestational diabetes mellitus
- NO:
-
Nitric oxide
- eNOS:
-
Endothelial NO synthase
- HUVECs:
-
Human umbilical vein endothelial cells
- hPMECs:
-
Human placental microvascular endothelial cells
- ARs:
-
Adenosine receptors
- A1AR:
-
A1 adenosine receptors
- A2AAR:
-
A2A adenosine receptors
- A2BAR:
-
A2B adenosine receptors
- A3AR:
-
A3 adenosine receptors
- hCAT-1:
-
Human cationic amino acid transporter 1
- hENT1:
-
Human equilibrative nucleoside transporters 1
- siRNA:
-
Short interference RNAs
- KDA1AR:
-
A1AR knockdown cells
- KDA2AAR:
-
A2AAR knockdown cells
- CHOP:
-
C/EBP homologous protein 10.
References
Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, Hod M, Kitzmiller JL, Kjos SL, Oats JN, Pettitt DJ, Sacks DA, Zoupas C (2007) Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 30:251–260
Colomiere M, Permezel M, Riley C, Desoye G, Lappas M (2009) Defective insulin signaling in placenta from pregnancies complicated by gestational diabetes mellitus. Eur J Endocrinol 160:567–578
Sobrevia L, Salsoso R, Sáez T, Sanhueza C, Pardo F, Leiva A (2015) Insulin therapy and fetoplacental vascular function in gestational diabetes mellitus. Exp Physiol 100:231–238
Vásquez G, Sanhueza F, Vásquez R, González M, San Martín R, Casanello P, Sobrevia L (2004) Role of adenosine transport in gestational diabetes-induced L-arginine transport and nitric oxide synthesis in human umbilical vein endothelium. J Physiol 560:111–122
Calabrò RS, Gervasi G, Bramanti P (2014) L-Arginine and vascular diseases: lights and pitfalls! Acta Biomed 85:222–228
Guzmán-Gutiérrez E, Westermeier F, Salomón C, González M, Pardo F, Leiva A, Sobrevia L (2012) Insulin-increased L-arginine transport requires A2A adenosine receptors activation in human umbilical vein endothelium. PLoS One 7:e41705
Read MA, Boura AL, Walters WA (1993) Vascular actions of purines in the foetal circulation of the human placenta. Br J Pharmacol 110:454–460
Westermeier F, Salomón C, Farías M, Arroyo P, Fuenzalida B, Sáez T, Salsoso R, Sanhueza C, Guzmán-Gutiérrez E, Pardo F, Leiva A, Sobrevia L (2015) Insulin requires normal expression and signalling of insulin receptor A to reverse gestational diabetes-reduced adenosine transport in human umbilical vein endothelium. FASEB J 29:37–49
Eltzschig HK (2009) Adenosine: an old drug newly discovered. Anesthesiology 111:904–915
Fredholm BB (2014) Adenosine—a physiological or pathophysiological agent? J Mol Med (Berl) 92:201–206
Antonioli L, Blandizzi C, Csóka B, Pacher P, Haskó G (2015) Adenosine signalling in diabetes mellitus—pathophysiology and therapeutic considerations. Nat Rev Endocrinol 11:228–241
Westermeier F, Salomón C, González M, Puebla C, Guzmán-Gutiérrez E, Cifuentes F, Leiva A, Casanello P, Sobrevia L (2011) Insulin restores gestational diabetes mellitus-reduced adenosine transport involving differential expression of insulin receptor isoforms in human umbilical vein endothelium. Diabetes 60:1677–1687
Maguire MH, Szabó I, Valkó IE, Finley BE, Bennett TL (1998) Simultaneous measurement of adenosine and hypoxanthine in human umbilical cord plasma using reversed-phase high-performance liquid chromatography with photodiode-array detection and on-line validation of peak purity. J Chromatogr B Biomed Sci Appl 707:33–41
Devés R, Boyd CA (1998) Transporters for cationic amino acids in animal cells: discovery, structure, and function. Physiol Rev 78:487–545
Mann GE, Yudilevich DL, Sobrevia L (2003) Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 83:183–252
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419
Wang YH, Wu HH, Ding H, Li Y, Wang ZH, Li F, Zhang JP (2013) Changes of insulin resistance and β-cell function in women with gestational diabetes mellitus and normal pregnant women during mid- and late pregnant period: a case–control study. J Obstet Gynaecol Res 39:647–652
González M, Gallardo V, Rodríguez N, Salomón C, Westermeier F, Guzmán-Gutiérrez E, Abarzúa F, Leiva A, Casanello P, Sobrevia L (2011) Insulin-stimulated L-arginine transport requires SLC7A1 gene expression and is associated with human umbilical vein relaxation. J Cell Physiol 262:2916–2924
Chin-Dusting JP, Willems L, Kaye DM (2007) L-arginine transporters in cardiovascular disease: a novel therapeutic target. Pharmacol Ther 116:428–436
Rajapakse NW, Johnston T, Kiriazis H, Chin-Dusting J, Du XJ, Kaye DM (2015) Augmented endothelial L-arginine transport ameliorates pressure overload induced cardiac hypertrophy. Exp Physiol. doi:10.1113/EP085250
Closs EI, Scheld JS, Sharafi M, Förstermann U (2000) Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters. Mol Pharmacol 57:68–74
Salomón C, Westermeier F, Puebla C, Arroyo P, Guzmán-Gutiérrez E, Pardo F, Leiva A, Casanello P, Sobrevia L (2012) Gestational diabetes reduces adenosine transport in human placental microvascular endothelium, an effect reversed by insulin. PLoS One 7:e40578
Simmons WW, Closs EI, Cunningham JM, Smith TW, Kelly RA (1996) Cytokines and insulin induce cationic amino acid transporter (CAT) expression in cardiac myocytes. Regulation of L-arginine transport and no production by CAT-1, CAT-2A, and CAT-2B. J Biol Chem 271:11694–11702
Ethier MF, Chander V, Dobson JG Jr (1993) Adenosine stimulates proliferation of human endothelial cells in culture. Am J Physiol 265:H131–H138
Yoneyama Y, Suzuki S, Sawa R, Yoneyama K, Power GG, Araki T (2002) Increased plasma adenosine concentrations and the severity of preeclampsia. Obstet Gynecol 100:1266–1270
Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev 63:1–34
Huang CC, Chiribau CB, Majumder M, Chiang CM, Wek RC, Kelm RJ Jr, Khalili K, Snider MD, Hatzoglou M (2009) A bifunctional intronic element regulates the expression of the arginine/lysine transporter Cat-1 via mechanisms involving the purine-rich element binding protein A (Pur alpha). J Biol Chem 284:32312–32320
Wang Q, Huang R, Yu B, Cao F, Wang H, Zhang M, Wang X, Zhang B, Zhou H, Zhu Z (2013) Higher fetal insulin resistance in Chinese pregnant women with gestational diabetes mellitus and correlation with maternal insulin resistance. PLoS One 8:e59845
Norman RJ, Wang JX, Hague W (2004) Should we continue or stop insulin sensitizing drugs during pregnancy? Curr Opin Obstet Gynecol 16:245–250
Verier-Mine O (2010) Outcomes in women with a history of gestational diabetes. Screening and prevention of type 2 diabetes. Literature review. Diabetes Metab 36:595–616
Löbner K, Knopff A, Baumgarten A, Mollenhauer U, Marienfeld S, Garrido-Franco M, Bonifacio E, Ziegler AG (2006) Predictors of postpartum diabetes in women with gestational diabetes mellitus. Diabetes 55:792–797
Acknowledgments
Authors thank Mrs Amparo Pacheco and Mrs Ninoska Muñoz from CMPL, Pontificia Universidad Católica de Chile, for excellent technical and secretarial assistance, respectively.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This works was supported by Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT 1150377, 1150344, and 11150083), Chile.
Conflict of interest
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Guzmán-Gutiérrez, E., Armella, A., Toledo, F. et al. Insulin requires A1 adenosine receptors expression to reverse gestational diabetes-increased L-arginine transport in human umbilical vein endothelium. Purinergic Signalling 12, 175–190 (2016). https://doi.org/10.1007/s11302-015-9491-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11302-015-9491-2